Cannabix and AlcoPro Enter MOU for Marijuana Breathalyzer Marketing
UF startup Cannabix Technologies announced it has entered into an MOU with AlcoPro to collaborate on marketing efforts for the Cannabix Marijuana Breathalyzer in the U.S.
Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia
Solid Biosciences Inc., a life sciences company that acquired UF startup AavantiBio, announced that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for SGT-212, the Company’s, AAV-based gene therapy candidate for the treatment of Friedreich’s ataxia (FA).
Rise Therapeutics Receives FDA IND Clearance To Initiate Clinical Testing of R-5780 in Cancer
UF startup Rise Therapeutics announced that the U.S. FDA has accepted its investigational new drug (IND) application to proceed with a cancer Phase 1 clinical trial for its program candidate, R-5780.
Caidya: Clinical Research Organization Raises $165 Million
Caidya, formed through the merger of dMed and UF startup Clinipace, announced the closing of a $165 million strategic growth investment from funds managed by Rubicon Founders, a U.S.-based healthcare investment firm focused on building transformational companies.
Genascence Announces Six-Month Results From Phase 1b DONATELLO Trial Indicating GNSC-001 Was Safe and Well Tolerated Across Multiple Dosing Arms
UF startup Genascence Corporation, a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal diseases with gene therapy, announced positive interim safety and biomarker results from the Phase 1b DONATELLO clinical trial evaluating GNSC-001.
Cannabix Technologies Announces Key Hardware Advancements to Marijuana Breathalyzer Technology
UF startup Cannabix Technologies Inc., developer of marijuana and alcohol breath testing devices, has announced that it has made significant updates to its Cannabix Marijuana Breathalyzer technology to meet suggested emerging regulatory requirements in preparation for marketing.
Atsena Therapeutics Initiates Part B of Phase I/II Clinical Trial Evaluating Gene Therapy ATSN-201 To Treat X-Linked Retinoschisis
UF startup Atsena Therapeutics, a clinical-stage gene therapy company specializing in genetic medicine to reverse or prevent blindness, has announced the initiation of Part B of the LIGHTHOUSE study, a Phase I/II clinical trial evaluating the subretinal injection of ATSN-201 for treating XLRS.
Solid Biosciences Announces FDA IND Clearance for First-in-Industry Dual Route of Administration Gene Therapy To Treat Both Neurologic and Cardiac Manifestations of Friedreich’s Ataxia
Solid Biosciences Inc., a biotechnology company that acquired UF startup AavantiBio, announced that the U.S. FDA has cleared its Investigational New Drug application for SGT-212 for the treatment of Friedreich’s ataxia.
Dose Escalation Completed for Rise Therapeutics’ R-3750 and R-2487 Clinical Trials
UF startup Rise Therapeutics, a clinical-stage biotechnology company developing novel oral immunotherapeutic medicines, announced that it has completed dose escalation enrollment stages for both its R-2487 and R-3750 clinical trials.
LightPath Technologies Begins Sustained Delivery of Infrared Assemblies to European Defense Customer
UF startup LightPath Technologies, Inc. announced that it has begun sustained delivery of infrared lens assemblies per the terms of the October 2024 Letter of Intent from a European defense customer for active duty use in first-person view (FPV) drone applications.
